New Global Threats are combated by Recombinant Vaccines
 |
| Recombinant Vaccines Market |
Recombinant vaccines are produced by using recombinant DNA
technology or genetic engineering for the prevention of lethal diseases in
human beings and animals. Recombinant vaccine is a biological preparation that
provides active acquired immunity against a certain disease. Whereas individual
being vaccinated produces antibodies against the protein antigen that protect a
person from contracting the disease upon attack from the pathogenic
microorganism. These vaccines functions on the immune response for diseases and
to have preventive measures against diseases caused by various bacteria, and
virus. These vaccines are much more advanced and effective as compare to
conventional vaccines in the prevention of diseases such as malaria, typhoid,
and human papillomavirus (HPV).
According to Coherent
Market Insights the global recombinant
vaccine market was valued at US$ 830.2 million in 2016 and is expected
to witness a robust CAGR of 6.0%
during the forecast period (2017 – 2025).
If medical science has achieved one resounding success
during the twentieth century, it has been the development of vaccines. After
reaching a peak with the eradication of the deadly smallpox virus, today new
challenges are faced. The latest versions of this therapy (recombinant
vaccines) are now being used to combat pathologies for which we still have no
cure. To bring an end to the last outbreak of Ebola in the Democratic Republic
of the Congo, the administration of a recombinant experimental vaccine was fundamental,
and the only vaccine that has shown some efficacy against HIV is precisely that
of a recombinant virus. Let’s learn how this treatment helps us fight global
threats.
Like traditional vaccines, recombinants teach the body to
fight certain infections effectively. However, while traditional vaccines use
the pathogen (or a part of it) that causes the disease being fought to activate
the immune system, recombinant vaccines are created on demand in the
laboratory, generating new microorganisms that don’t produce infection. Juan
García Arriaza, a researcher at the National Centre for Biotechnology in Spain,
tells OpenMind what the process is like: “Recombinant technology involves
introducing into any vector—usually a virus or a bacteria that doesn’t cause
disease—regions of the pathogen called antigens, which we know are immunogenic;
that is, they have the capacity to activate the immune system.” This technique,
in addition to provoking a strong immune response, also avoids some of the
pitfalls of vaccine development: “As we are only introducing a fragment of the
pathogen, we’ll never be able to cause the disease that we are trying to
prevent because people are never being vaccinated with the germ. There’s 100%
certainty that you won’t produce the illness,” assures Arriaza.
Comments
Post a Comment